Sun, Nov 23, 2014, 8:45 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

  • buy_n_hold_2001 buy_n_hold_2001 Sep 17, 2012 9:43 PM Flag

    Dr. Wirth leaving

    Why??

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The resignation of a chief science officer while preparing for a milestone clinical trial (in relation to this small company's history) is not a good thing. I would venture to say that there is either conflict over the direction of the trial or frustration at the delays. Resigning for 'personal reasons' means the gentleman is exiting without a place to go, either of his own doing or by being pushed from inside. I don't know much about his interim replacement, but putting their bios side by side, I'd say they are not equals.

      Google Ed Wirth Invivo and Brian Hess Invivo to compare backgrounds. This forum won't allow me to post links to the company's web pages.

      I'm beginning to get bearish on this company.

      • 1 Reply to jagrantjr
      • mytradesinc@sbcglobal.net mytradesinc Sep 18, 2012 12:29 PM Flag

        I think Frank knows what he is doing........I think Hess's resume is MORE impressive...our goal is to get through FDA tape....that's what this guys gonna do.............!!!

        Prior to joining the Company, Mr. Hess spent the previous eight years at Stryker developing biomaterial technologies for the orthopedic market, and he has led multiple product development teams through the FDA process. Mr. Hess was instrumental in developing HydroSetTM, an injectable calcium phosphate based bone substitute, from concept to product launch. The product has become the market-leading bone scaffold, and Stryker awarded Mr. Hess and his team with "Best Technology" and "Best Team Synergy" for their work on this critical product. Mr. Hess also won several research and development awards during his tenure at Stryker. Most notably he was named "Co-Innovator of the Year" in 2010 within Stryker Orthopeadics.


        Said InVivo CEO Frank Reynolds, "Over the course of the last year we have watched Brian deepen his skill sets and emerge as a leader for InVivo. We are confident that the product development and clinical programs at InVivo continue to remain on track."

        Commented Robert Langer, ScD, InVivo Therapeutics co-founder and scientific advisory board member, "I continue to be very excited and pleased about the wonderful science and biomaterials work that is going on at InVivo, and I'm very much hopeful that this research will help patients with neurotrauma injuries. Brian has an extremely strong background in biomaterials, and the team and I are looking forward to working with him in this capacity."

        Sentiment: Buy

 
NVIV
1.31+0.04(+3.15%)Nov 21 3:53 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
GameStop Corp.
NYSEFri, Nov 21, 2014 4:04 PM EST
Intuit Inc.
NasdaqGSFri, Nov 21, 2014 4:00 PM EST